Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,955 total articles
MannKind's FDA pediatric approval for Afrezza plus positive ADA 2026 data materially expand addressable market and catalyze adoption. With Q1 2026 revenue growth, a sub-$1.3B market cap and a clear commercialization runway, MannKind warrants a long trade for investors willing to tolerate biotech execution risk. Trade plan included with entry, stop …
ASE Technology (ASX) is benefiting from sustained demand for advanced semiconductor packaging. With improving margin dynamics, bullish technical momentum and a market cap of roughly $93.2B, a tactical long trade offers asymmetric upside toward the 52-week range while keeping risk defined under recent support.
Par Pacific (PARR) is a small-cap refiner with island-centric logistics that benefit disproportionately from tight global fuel markets. Low leverage, robust free cash flow and deeply depressed multiples versus cyclical upside make a measured long here attractive. Trade plan: enter at $77.78, stop $70.00, target $100.00 over a long-term (180 trading…
Corning is one of the clearest ways to play AI infrastructure beyond chips. The company sits squarely in the optical connectivity layer that hyperscalers are racing to upgrade, and recent multi-billion-dollar deals plus accelerating revenue and free cash flow create a compelling risk/reward. This trade idea lays out an actionable long with entry, s…
Seanergy Maritime (SHIP) looks attractive at current levels. The company is expanding its scrubber-fitted Capesize newbuild program, has locked-in meaningful charter coverage at ~$29.3k/day, sports a modest PE of 5.6 and a 3.6% yield, and trades well below its 52-week high. Recommended: long with a clear entry, stop and target over a 180 trading-da…
Core & Main is a specialty distributor for water, wastewater, storm drainage and fire protection products. The stock has pulled back near $46 and trades at a reasonable P/E and EV/EBITDA given steady free cash flow generation. We recommend buying CNM at $46.00 with a $60.00 target and a $41.50 stop, horizon: long term (180 trading days).
Calumet is trading near 52-week highs after a run of operational headlines and a $100M note redemption. The actionable idea is a mid-term long that leans on a successful scale-up of the Montana Renewables - Great Falls (MRL) asset, continued specialty-products strength, and balance-sheet progress. Key risks are leverage, commodity cyclicality and e…
Intuit’s share price still trades well below its 52-week peak after a painful reset driven by disappointing TurboTax results, layoffs and a wave of negative headlines. That swing has created an attractive entry for patient buyers: the company generates roughly $7.8B in free cash flow, trades around 20x earnings and carries an enterprise value rough…
Kulicke & Soffa (KLIC) sits squarely in the ‘packaging’ layer of semiconductor manufacturing where AI-driven demand for advanced wafer-level and chip-scale bonding is expanding addressable market and pricing power. The company has clean financials, steady cash flow, and momentum that supports a long trade targeting recovery toward the prior high as…
Fluence is trading at roughly $13.30 after a volatile 2026 run. Market cap sits near $2.19B and enterprise value near $2.47B, while negativity in earnings and free cash flow keep fundamentals strained. Recent contract wins and pre-qualification with hyperscalers plus partnerships with Nvidia make upside plausible, but execution, margins and working…
Stagwell's shift from traditional agency work toward AI-enabled digital transformation and a turbocharged Marketing Cloud business is producing tangible revenue and cash-flow improvements. The shares trade at a reasonable price-to-sales on a $2.9B revenue base, while momentum indicators and sizable insider/fund buys point to further upside. This is…
GE Aerospace checks a rare combination: heavy commercial backlog, clear production investment, strong free cash flow, and technically constructive price action. I lay out an actionable long trade with entry, stop and target for a 180-trading-day horizon and explain the thesis, valuation framing, catalysts and risks.
Consumers Bancorp reported Q4 FY2025 results showing net income up 9.0%, a net interest margin of 3.39% and 7.2% loan growth while expanding branches in Ohio. Technicals show strong momentum but an overbought RSI. This is a tactical long trade for active accounts with an explicit entry, stop and target and a mid-term horizon (45 trading days).
ADMA Biologics has taken a beating on accounting allegations and a sharp reevaluation of recent growth. That pain is priced in: EV/EBITDA sits near 10 and free cash flow is roughly $116M. We lay out a mid-term swing trade that buys the post-reset story while explicitly protecting downside around structural support.
Definium Therapeutics has the makings of a classic biotech asymmetric trade: a mid-cap market cap of roughly $5.7B, low leverage, heavy short interest, and an upcoming September 2026 catalyst tied to its CNS program. If the market validates the reported positive DT120 oral disintegrating tablet (ODT) data across two indications, upside to the mid-$…
Caledonia's Q2 production beats and the Bilboes reserve read strengthen the fundamental story. The stock looks attractively valued at a $538M market cap and a PE of ~6.8, but lingering Zimbabwe royalty / tax uncertainty, legal scrutiny, and execution risk on growth projects argue for a tactical, mid-term long rather than a buy-and-hold.
National Energy Services Reunited (NESR) has moved from cyclic recovery to execution: new cementing wins, improving revenue scale and shrinking volatility justify a higher multiple. We lay out a swing trade with entry, stop and target, explain the fundamental rationale and list catalysts and risks.
Lumentum (LITE) has been one of 2025-26's biggest winners, but the bull case isn't purely momentum — hyperscaler capex, Nvidia strategic commitments, and a multi-year silicon-photonics bottleneck argue for durable demand. Valuation is rich on headline multiples, yet the market is paying today for a potential oligopoly supplier of high-bandwidth opt…
Alexandria Real Estate Equities (ARE) offers an attractive risk-reward today: a recurring quarterly payout that equates to a 5.9% yield at current prices, a price-to-book near 0.53 that implies roughly a 50% discount to tangible book, and an enterprise valuation that feels stretched only because of temporary operating headwinds. This trade idea lay…
Grail's failed NHS Galleri readout on 08/01/2026 triggered headline selling across genomic names. Illumina (ILMN) has been swept up, but the company still generates strong free cash flow ($931M), carries manageable leverage (debt/equity ~0.7), and trades near $192.93 with a market cap of about $29.13B. This trade idea lays out an actionable long: e…
CytomX (CTMX) is a clinical-stage oncology biotech advancing varsetatug masetecan (Varseta-M) with upside driven by clinical progress and partnership milestones. A $250M equity raise in March 2026 and a June expansion of the Regeneron collaboration meaningfully reduce near-term dilution risk and extend runway, creating a favorable risk-reward for a…
Greggs is a resilient, cash-generative UK bakery chain trading at a valuation that looks fair but not demanding. A disciplined long entry here balances upside from execution and new product momentum against macro and commodity risks. Trade plan: enter at $25.00, target $30.00, stop $21.00 — horizon: long term (180 trading days).
Cognex (CGNX) is a profitable, cash-generative machine vision leader that the market appears to be discounting relative to its exposure to AI-driven data center and semiconductor supply chains. Strong margins, zero financial debt, and $268M in free cash flow underpin a long-term trade with a favorable risk-reward.
Watts Water Technologies is benefiting from AI-driven data-center infrastructure demand and a recovering Europe after a tough 2025. With a $14.2B market cap, clean balance sheet and strong free cash flow, the stock looks set to re-rate. This is a tactical long idea with a mid-term (45 trading days) horizon: enter on strength at $386.37, stop at $36…
908 Devices makes small, mission-critical mass spectrometers used by customs, food labs, and biotech clients. Recent contract wins and steady top-line growth (Q2 2025 revenue $13.0M, +14% YoY) alongside a manageable enterprise value (~$346M) support a tactical long. Expect near-term volatility; plan for a defined entry, stop and target over a 180 t…
